Photo:
curegt.org
Sep 2, 2026, 06:38
Gene Therapy for Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
Glanzmann’s Research Foundation shared a post on LinkedIn:
“We’re revisiting a promising 2025 study that offers a hopeful look at the future of Glanzmann Thrombasthenia gene therapy.
Researchers successfully used gene transfer to increase production of the platelet receptor affected by GT in human cells.
Although this was laboratory research, the findings support the next step: testing the approach in stem cells from people with GT.
We’ve broken down the research and what it could mean for patients and families in an easy-to-understand article.”
Other posts about Glanzmann’s Research Foundation on Hemostasis Today.
-
Oct 18, 2026, 08:02Neda Ashayeri: Global Perspectives on Hemophilia and Rare Bleeding Disorders in Abu Dhabi
-
Oct 18, 2026, 07:55Anu Thomas: A Stepwise Laboratory Approach to Positive IAT and Pretransfusion Compatibility
-
Oct 18, 2026, 07:49Matthew Hazell: Molecular Matching and the Future of Transfusion Practice
-
Oct 18, 2026, 07:05Behnood Bikdeli: Vasculearn Network Highlights Expert Perspectives on PE Risk Stratification and Advanced Therapies
-
Oct 18, 2026, 06:27Gregory Makris: NEJM Study Supports Earlier Catheter-Directed Intervention in Intermediate-High–Risk PE
-
Oct 18, 2026, 06:26Danny Hsu: BLOOD 2026 Return to Aotearoa
-
Oct 18, 2026, 02:43Priya Sriskandarajah: Diagnosis and Management of PV and JAK2-Unmutated Erythrocytosis
-
Oct 18, 2026, 02:41C. Michael Gibson: A Meta-Analysis of DOACs and DAPT After Left Atrial Appendage Closure
-
Oct 18, 2026, 02:27What Hematologists Should Remember About the Person Behind the Platelet Count – ASH